43.19
前日終値:
$42.99
開ける:
$42.83
24時間の取引高:
1.52M
Relative Volume:
1.00
時価総額:
$5.06B
収益:
$3.22M
当期純損益:
$-576.40M
株価収益率:
-8.0279
EPS:
-5.38
ネットキャッシュフロー:
$-407.05M
1週間 パフォーマンス:
-4.93%
1か月 パフォーマンス:
-8.98%
6か月 パフォーマンス:
-17.48%
1年 パフォーマンス:
-38.40%
Cytokinetics Inc Stock (CYTK) Company Profile
名前
Cytokinetics Inc
セクター
電話
(650) 624-3000
住所
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
CYTK
Cytokinetics Inc
|
43.19 | 5.06B | 3.22M | -576.40M | -407.05M | -5.38 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-07 | 開始されました | Citigroup | Buy |
2025-01-22 | 開始されました | Stifel | Buy |
2024-11-08 | 開始されました | RBC Capital Mkts | Outperform |
2024-08-13 | ダウングレード | Goldman | Buy → Neutral |
2024-01-24 | ダウングレード | UBS | Buy → Neutral |
2024-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2023-11-09 | 開始されました | Goldman | Buy |
2023-11-07 | 開始されました | B. Riley Securities | Buy |
2023-08-15 | 開始されました | SVB Securities | Outperform |
2023-02-17 | 開始されました | BofA Securities | Neutral |
2022-12-23 | 繰り返されました | Needham | Buy |
2022-12-20 | 開始されました | Truist | Buy |
2022-10-11 | 開始されました | UBS | Buy |
2022-01-28 | 開始されました | Goldman | Buy |
2021-12-22 | 開始されました | Oppenheimer | Outperform |
2021-12-10 | 開始されました | JP Morgan | Overweight |
2021-10-07 | 開始されました | Jefferies | Buy |
2021-03-12 | 開始されました | Wolfe Research | Outperform |
2021-02-18 | 開始されました | Barclays | Overweight |
2021-01-20 | 繰り返されました | H.C. Wainwright | Buy |
2020-10-29 | 開始されました | Goldman | Neutral |
2020-07-10 | 開始されました | Raymond James | Strong Buy |
2020-05-05 | 開始されました | Mizuho | Buy |
2020-04-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2018-09-21 | 開始されました | Cantor Fitzgerald | Overweight |
2018-09-10 | 再開されました | Morgan Stanley | Equal-Weight |
2017-11-22 | 繰り返されました | Morgan Stanley | Overweight |
2017-11-22 | ダウングレード | Needham | Strong Buy → Buy |
2017-11-21 | 繰り返されました | H.C. Wainwright | Buy |
2017-07-31 | 開始されました | Morgan Stanley | Overweight |
2017-03-08 | 開始されました | Rodman & Renshaw | Buy |
2017-02-06 | アップグレード | Needham | Buy → Strong Buy |
2016-12-16 | 開始されました | Cantor Fitzgerald | Overweight |
2016-07-28 | 繰り返されました | Needham | Buy |
2015-11-10 | 繰り返されました | FBR Capital | Outperform |
2015-11-09 | 繰り返されました | ROTH Capital | Buy |
2015-07-24 | 繰り返されました | MLV & Co | Buy |
2014-12-31 | 繰り返されました | ROTH Capital | Buy |
2014-11-04 | アップグレード | MLV & Co | Hold → Buy |
2014-04-28 | 繰り返されました | Needham | Buy |
すべてを表示
Cytokinetics Inc (CYTK) 最新ニュース
Cytokinetics Announces Data From Phase 1 Study of CK-4021586 - Marketscreener.com
Is Cytokinetics, Incorporated (CYTK) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Cytokinetics (CYTK) Moves 5.4% Higher: Will This Strength Last? - Nasdaq
Cytokinetics Launches EARTH-HCM: An Interactive Tool for Understanding Hypertrophic Cardiomyopathy and Improving Access to Care - Nasdaq
Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community - The Manila Times
Cytokinetics EVP Malik sells $87,160 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Malik sells $87,160 in stock - Investing.com
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics announces inducement grants under Nasdaq listing rule 5635(C)(4) -March 18, 2025 at 04:15 pm EDT - Marketscreener.com
Cytokinetics Strengthens Workforce: 13 New Hires Secure Strategic Equity Awards - StockTitan
H.C. Wainwright maintains Buy on Cytokinetics, $120 target By Investing.com - Investing.com UK
Cytokinetics Executives Engage in Multiple Stock Transactions - TradingView
Cytokinetics Incorporated: Aficamten's Differentiated Profile and Market Potential Is Powering Our Hopefulness! - Smartkarma
UBS Lowers Price Target on Cytokinetics to $47 From $61, Maintains Neutral Rating -March 17, 2025 at 11:27 am EDT - Marketscreener.com
Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo - The Manila Times
Cytokinetics Announces Five Presentations at the American College of Cardiology Annual ... - NRToday.com
Cytokinetics’ EVP sells $4,500 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $4,500 in stock By Investing.com - Investing.com UK
Cytokinetics’ EVP sells $4,500 in stock - Investing.com India
Cytokinetics EVP Callos Andrew sells shares for $1.17 million By Investing.com - Investing.com South Africa
Cytokinetics EVP Callos Andrew sells shares for $1.17 million - Investing.com
Charles Schwab Investment Management Inc. Raises Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - Defense World
Cytokinetics at Barclays Healthcare Conference: Strategic Launch Plans By Investing.com - Investing.com UK
Cytokinetics at Leerink’s Global Healthcare Conference: Strategic Pipeline Insights By Investing.com - Investing.com Australia
Citi maintains Cytokinetics stock Buy rating, $86 target By Investing.com - Investing.com Canada
Promising Progress and Positive Outlook for Cytokinetics’ Aficamten in oHCM Treatment - TipRanks
RBC Capital stays bullish on Cytokinetics on lack of AdCom in aficamten view - TipRanks
Cytokinetics regulatory update ‘incrementally positive,’ says Morgan Stanley - TipRanks
Why Have Cytokinetics Stocks Plummeted? - TipRanks
Cytokinetics says FDA does not plan advisory committee meeting for aficamten NDA - TipRanks
Cytokinetics maintains expectation For Differentiated Label & Risk Mitigation Profile for Aficamten if approved By FDA - Marketscreener.com
Cytokinetics Completes Midcycle Review with FDA for Aficamten - TipRanks
Robert I. Blum Sells 16,970 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - Defense World
B. Riley Brokers Reduce Earnings Estimates for Cytokinetics - Defense World
Cytokinetics Stock: Executives Sell Shares Despite Growth Outlook - sharewise
Cytokinetics EVP Fady Ibraham sells $356,025 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $144,565 in stock By Investing.com - Investing.com Australia
Cytokinetics EVP Andrew Callos sells $144,565 in stock - Investing.com
Cytokinetics CEO Robert Blum sells shares worth $737,176 - Investing.com
Cytokinetics EVP Fady Ibraham sells $356,025 in stock - Investing.com India
Cytokinetics Executives Engage in Stock Transactions - TradingView
Cytokinetics CEO Robert Blum sells shares worth $737,176 By Investing.com - Investing.com UK
Morgan Stanley raises Cytokinetics stock to Overweight, $67 target By Investing.com - Investing.com UK
What is B. Riley’s Forecast for Cytokinetics Q1 Earnings? - Defense World
Cytokinetics assumed with an Overweight at Morgan Stanley - TipRanks
Cytokinetics Positioned for Growth: Buy Rating Backed by Aficamten’s Market Potential and Upcoming PDUFA Date - TipRanks
Cytokinetics Executives Cash In: Massive Stock Sales Unveiled! - TipRanks
Insider Sell Alert: Fady Malik Sells Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Insider Sell: Andrew Callos Sells Shares of Cytokinetics Inc (CY - GuruFocus.com
Cytokinetics Inc (CYTK) 財務データ
収益
当期純利益
現金流量
EPS
Cytokinetics Inc (CYTK) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Malik Fady Ibraham | EVP Research & Development |
Mar 18 '25 |
Sale |
43.58 |
2,000 |
87,160 |
140,455 |
Callos Andrew | EVP, Chief Commercial Officer |
Mar 17 '25 |
Sale |
44.38 |
2,775 |
123,154 |
34,888 |
Malik Fady Ibraham | EVP Research & Development |
Mar 17 '25 |
Sale |
44.38 |
4,389 |
194,784 |
101,005 |
Blum Robert I | President & CEO |
Mar 17 '25 |
Sale |
44.38 |
12,648 |
561,318 |
326,533 |
Blum Robert I | President & CEO |
Mar 17 '25 |
Sale |
44.65 |
25,000 |
1,116,250 |
339,181 |
Callos Andrew | EVP, Chief Commercial Officer |
Mar 17 '25 |
Option Exercise |
23.26 |
20,900 |
486,134 |
58,563 |
Callos Andrew | EVP, Chief Commercial Officer |
Mar 17 '25 |
Sale |
45.14 |
20,900 |
943,426 |
37,663 |
Callos Andrew | EVP, Chief Commercial Officer |
Mar 14 '25 |
Option Exercise |
23.26 |
100 |
2,326 |
37,763 |
Callos Andrew | EVP, Chief Commercial Officer |
Mar 14 '25 |
Sale |
45.00 |
100 |
4,500 |
37,663 |
大文字化:
|
ボリューム (24 時間):